Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus VERARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus VERARD.
DILACOR XR vs VERARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Verard (vericiguat) is a soluble guanylate cyclase (sGC) stimulator. It sensitizes sGC to endogenous nitric oxide (NO) and directly stimulates sGC independently of NO, thereby increasing cyclic guanosine monophosphate (cGMP) production, leading to vasodilation and anti-remodeling effects in the heart and vasculature.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
400 mg orally twice daily for 14 days
None Documented
None Documented
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal elimination half-life 12-15 hours; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Renal excretion (70% unchanged, 20% as inactive metabolites), biliary/fecal (10%).
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker